The global minimally invasive glaucoma surgery (MIGS) devices market was valued at USD 539.64 million in 2023 and it is predicted to surpass around USD 911.35 million by 2033 with a CAGR of 5.38% from 2024 to 2033.
The minimally invasive glaucoma surgery (MIGS) devices market is witnessing a transformative phase, driven by advancements in ophthalmic technology and a paradigm shift towards less invasive surgical interventions for glaucoma management. This market overview aims to provide a comprehensive snapshot of key aspects shaping the landscape of MIGS devices.
The minimally invasive glaucoma surgery (MIGS) devices market is experiencing robust growth, driven by several key factors. Firstly, the escalating global incidence of glaucoma underscores the imperative for advanced and less invasive treatment modalities, positioning MIGS devices as a pivotal solution in meeting this demand. Technological advancements play a paramount role, as continuous innovation enhances the precision, safety, and efficacy of MIGS procedures. Patient preference for minimally invasive interventions, marked by reduced postoperative discomfort and expedited recovery, is another significant growth factor. Additionally, the aging global population, prone to an elevated risk of glaucoma, contributes to the expanding market. As stakeholders focus on refining MIGS device technologies and overcoming regulatory challenges, the market is poised for sustained growth, shaping the landscape of glaucoma management.
Report Coverage | Details |
Market Size in 2023 | USD 539.64 million |
Revenue Forecast by 203 | USD 911.35 million |
Growth rate from 2024 to 2033 | CAGR of 5.38% |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
The glaucoma drainage implant segment held the largest market share of around 34% in 2023. Glaucoma drainage implants are very efficient as it is a viable surgical approach to address glaucoma. These devices are typically suggested when alternative treatments like medications and laser therapy prove insufficient in managing the condition. These implants help in improved surgical techniques, targeted medication delivery, and patient comfort. The Ahmed Glaucoma Valve (AGV), Baerveldt Glaucoma Implant, Molteno Implant, Krupin Valve, and other glaucoma drainage devices are a few examples of the numerous types of glaucoma drainage devices available.
The stent segment is anticipated to grow at the fastest CAGR during the forecast period. The purpose of these stents is to establish an alternative route for the drainage of aqueous humor, the fluid present within the eye, to lowering intraocular pressure (IOP). However, the stent is not suitable for all glaucoma patients. The decision regarding treatment options, including the use of the stent, is based on an individual's particular condition, and the type of glaucoma they have.
The trabecular meshwork bypass segment accounted for the largest revenue share in 2023. In cases of glaucoma, the trabecular meshwork may become obstructed or less effective, resulting in elevated intraocular pressure (IOP). This increased pressure can harm the optic nerve and lead to vision loss. Bypassing the trabecular meshwork offers numerous advantages and applications in the treatment and management of glaucoma, such as lowering intraocular pressure, and preserving optic nerve health. This segment is further sub-segmented as stent placement and by tissue excision, in which the stent placement segment dominated the segment in 2023.
Schlemm’s canal implants segment is estimated to register the fastest CAGR during the forecast period. Schlemm's canal implants, also recognized as micro-invasive glaucoma surgery (MIGS) devices that focus on Schlemm's canal, constitute a group of surgical procedures tailored to address intraocular pressure (IOP) in individuals with glaucoma. These implants are utilized to establish a fresh route for the drainage of aqueous humor, the transparent fluid within the eye, by utilizing Schlemm's canal, an integral part of the eye's natural drainage system.
Based on end-use, the hospitals segment dominated the market in 2023. Ophthalmic surgeries are commonly performed by well-trained surgical teams within hospital environments, consisting of both inpatient and outpatient settings. Hospitals provide a controlled, sterile environment that is highly conducive to such surgeries. To ensure the successful and safe execution of these operations, surgeons, anesthesiologists, nurses, and other medical specialists collaborate within the hospital setting. Hospitals are also known for adhering to strict regulatory and safety standards, thereby guaranteeing a high level of patient safety during ophthalmic surgeries. This assurance is beneficial for both patients and surgeons. Moreover, hospitals are equipped to handle any potential complications and offer comprehensive care to patients undergoing glaucoma surgery. Thus, all these factors contribute to the segment growth.
The ophthalmic clinic segment is expected to grow at the fastest CAGR over the forecast period. Ophthalmic clinics provide several benefits, including convenience, and shorter waiting periods, and are patient-centric, leading to increased patient satisfaction. Moreover, these clinics are often more cost-effective due to their reduced overhead expenses, potentially making eye surgeries more accessible and affordable for patients. The specialized concentration on eye care within these clinics allows for a higher level of expertise and precision in the field. In addition, outpatient settings may lower the risk of hospital-acquired infections, making them a preferred choice for surgeries that can be safely performed outside of a hospital.
North America dominated the overall market in 2023. The significant factors driving the regional market growth include the rapidly expanding geriatric population and the increasing incidence of glaucoma. Furthermore, the adoption of reimbursement models for ophthalmic care and the implementation of stringent regulatory measures focused on ensuring patient safety are anticipated to stimulate the demand for ophthalmic devices in this region. Also, the presence of key market players in the region involved in developing advanced products is expected to boost the regional market growth.
U.S. dominated the market in North America region. The presence of key market players in the country, a favorable reimbursement scenario that provides access to healthcare services to a large portion of the population, and the presence of skilled healthcare professionals in the country are among the major factors contributing to the market growth.
Asia Pacific region is expected to grow at the fastest CAGR during the forecast period. This growth is primarily attributed to several factors, including the advancements in healthcare infrastructure, the increasing prevalence of eye disorders like glaucoma, and growing patient awareness in the region. In addition, the growth can be linked to the growing outsourcing activities for ophthalmology devices by major industry players like Alcon, Inc. Furthermore, the growing awareness surrounding advanced corrective vision treatments plays a pivotal role in the expansion of emerging economies, particularly in countries such as China and India.
In 2023, China held the greatest share of the Asia Pacific region's market for minimally invasive glaucoma surgery devices. In China, the regulatory process for product approvals is less stringent, allowing innovative products to enter the market more easily. Furthermore, the availability of resources enables innovations in technology at lower costs, resulting in an expansion in the number of manufacturing facilities in the country.
By Product
By Surgery Method
By End-use
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Product Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Minimally Invasive Glaucoma Surgery (MIGS) Devices Market
5.1. COVID-19 Landscape: Minimally Invasive Glaucoma Surgery (MIGS) Devices Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market, By Product
8.1. Minimally Invasive Glaucoma Surgery (MIGS) Devices Market, by Product, 2024-2033
8.1.1 Valves
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Glaucoma Drainage Implant
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Glaucoma Tube Shunts
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Stents
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market, By Surgery Method
9.1. Minimally Invasive Glaucoma Surgery (MIGS) Devices Market, by Surgery Method, 2024-2033
9.1.1. Trabecular Meshwork Bypass
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Suprachoroidal Space Implants
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Subconjunctival Space Implants
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Schlemm’s Canal Implants
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Gonioscopy-assisted Transluminal Trabeculectomy
9.1.5.1. Market Revenue and Forecast (2021-2033)
9.1.6. Endocyclophotocoagulation
9.1.6.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market, By End-use
10.1. Minimally Invasive Glaucoma Surgery (MIGS) Devices Market, by End-use, 2024-2033
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Ophthalmic Clinics
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Others Surgical Centers
10.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2021-2033)
11.1.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.1.3. Market Revenue and Forecast, by End-use (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.1.4.3. Market Revenue and Forecast, by End-use (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.1.5.3. Market Revenue and Forecast, by End-use (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2021-2033)
11.2.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.2.3. Market Revenue and Forecast, by End-use (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.2.4.3. Market Revenue and Forecast, by End-use (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.2.5.3. Market Revenue and Forecast, by End-use (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.2.6.3. Market Revenue and Forecast, by End-use (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.2.7.3. Market Revenue and Forecast, by End-use (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2021-2033)
11.3.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.3.3. Market Revenue and Forecast, by End-use (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.3.4.3. Market Revenue and Forecast, by End-use (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.3.5.3. Market Revenue and Forecast, by End-use (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.3.6.3. Market Revenue and Forecast, by End-use (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.3.7.3. Market Revenue and Forecast, by End-use (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.4.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.4.3. Market Revenue and Forecast, by End-use (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.4.4.3. Market Revenue and Forecast, by End-use (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.4.5.3. Market Revenue and Forecast, by End-use (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.4.6.3. Market Revenue and Forecast, by End-use (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.4.7.3. Market Revenue and Forecast, by End-use (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.5.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.5.3. Market Revenue and Forecast, by End-use (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.5.4.3. Market Revenue and Forecast, by End-use (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Surgery Method (2021-2033)
11.5.5.3. Market Revenue and Forecast, by End-use (2021-2033)
Chapter 12. Company Profiles
12.1. Alcon, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Glaukos Corporation.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Johnson & Johnson Vision.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. AbbVie Inc. (Allergan Plc.).
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Corza Ophthalmology.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Carl Zeiss Meditec AG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Katalyst Surgical.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Lumenis Ltd
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Ziemer Ophthalmic Systems AG.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Iridex Corporation
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms